Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of “Buy” by Analysts

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has been assigned an average recommendation of “Buy” from the eight ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, five have given a buy rating and two have issued a strong buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $32.20.

A number of equities research analysts have recently issued reports on EYPT shares. TD Cowen upgraded Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Friday, December 19th. Citigroup lifted their price target on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Monday. Cantor Fitzgerald upgraded Eyepoint Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, November 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Thursday, January 22nd. Finally, Chardan Capital increased their price objective on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th.

Eyepoint Pharmaceuticals Stock Down 6.0%

EYPT opened at $14.03 on Friday. Eyepoint Pharmaceuticals has a 12-month low of $3.91 and a 12-month high of $19.11. The business has a 50 day moving average of $15.40 and a 200-day moving average of $14.45. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -4.44 and a beta of 1.72.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings results on Wednesday, March 4th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.03). The company had revenue of $0.62 million during the quarter, compared to analyst estimates of $1.01 million. Eyepoint Pharmaceuticals had a negative net margin of 739.39% and a negative return on equity of 88.31%. As a group, analysts expect that Eyepoint Pharmaceuticals will post -2.13 earnings per share for the current year.

Insider Activity at Eyepoint Pharmaceuticals

In related news, insider Ramiro Ribeiro sold 42,544 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $17.10, for a total transaction of $727,502.40. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 4.46% of the company’s stock.

Institutional Trading of Eyepoint Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. State of Alaska Department of Revenue bought a new position in shares of Eyepoint Pharmaceuticals during the third quarter worth approximately $50,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Eyepoint Pharmaceuticals by 51.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock valued at $74,000 after buying an additional 1,358 shares during the period. Russell Investments Group Ltd. acquired a new stake in Eyepoint Pharmaceuticals during the third quarter worth approximately $76,000. Tower Research Capital LLC TRC grew its position in Eyepoint Pharmaceuticals by 218.3% during the second quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock worth $82,000 after buying an additional 5,967 shares in the last quarter. Finally, California State Teachers Retirement System increased its stake in Eyepoint Pharmaceuticals by 20.6% during the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after acquiring an additional 794 shares during the period. Institutional investors own 99.41% of the company’s stock.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.